PMID- 38041905
OWN - NLM
STAT- MEDLINE
DCOM- 20240115
LR  - 20240115
IS  - 1873-5150 (Electronic)
IS  - 0887-8994 (Linking)
VI  - 151
DP  - 2024 Feb
TI  - Role of Perampanel in the Management of Pediatric Epilepsies in Asia: Expert 
      Opinion.
PG  - 5-16
LID - S0887-8994(23)00350-8 [pii]
LID - 10.1016/j.pediatrneurol.2023.09.023 [doi]
AB  - Management of pediatric epilepsies poses unique challenges around diagnosis, 
      treatment options, comorbidities, and the potential for these factors to interact 
      with processes in the developing brain. In pediatric patients, broad-spectrum 
      antiseizure medications (ASMs) with minimal potential for adverse events (AEs) 
      and limited impact on cognition and behavior are preferred. Perampanel is a 
      first-in-class ASM with broad-spectrum efficacy, a tolerable safety profile, 
      minimal negative impact on cognitive function, and other features that make it a 
      viable treatment option in this patient population. However, evidence and 
      experience of its use in pediatric patients are less extensive than in adult 
      patients. Experts in pediatric epilepsy across the region convened at a series of 
      meetings to discuss the use of perampanel in pediatric patients, including dose 
      optimization, AE prevention and management, and considerations in particular 
      groups. This article summarizes key evidence for perampanel in the pediatric 
      population and consolidates the experts' recommendations for using the ASM in 
      managing pediatric epilepsies.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Lee, Wang-Tso
AU  - Lee WT
AD  - Department of Pediatrics, National Taiwan University Children's Hospital, Taipei, 
      Taiwan.
FAU - Chan, Derrick Wei Shih
AU  - Chan DWS
AD  - Neurology Service, KK Women's and Children's Hospital, Singapore.
FAU - Gulati, Sheffali
AU  - Gulati S
AD  - Center of Excellence and Advanced Research on Childhood Neurodevelopmental 
      Disorders, Child Neurology Division, Department of Paediatrics, All India 
      Institute of Medical Sciences, New Delhi, India.
FAU - Likasitwattanakul, Surachai
AU  - Likasitwattanakul S
AD  - Division of Neurology, Department of Pediatrics, Faculty of Medicine, Siriraj 
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - Lim, Byung Chan
AU  - Lim BC
AD  - Department of Pediatrics, Seoul National University Children's Hospital, Seoul, 
      South Korea.
FAU - Okumura, Akihisa
AU  - Okumura A
AD  - Department of Pediatrics, Aichi Medical University, Nagakute, Japan.
FAU - Sanchez-Gan, Benilda
AU  - Sanchez-Gan B
AD  - Division of Pediatric Neurology, Departments of Pediatrics and Neurosciences, 
      University of the Philippines, Philippine General Hospital, Manila, Philippines.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Neurology, Children's Hospital of Fudan University, Shanghai, 
      China.
FAU - Liu, Kam Tim
AU  - Liu KT
AD  - Department of Paediatrics and Adolescent Medicine, Pamela Youde Nethersole 
      Eastern Hospital and Queen Mary Hospital, Hong Kong SAR, China. Electronic 
      address: liuktn@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231004
PL  - United States
TA  - Pediatr Neurol
JT  - Pediatric neurology
JID - 8508183
RN  - H821664NPK (perampanel)
RN  - 0 (Anticonvulsants)
RN  - 0 (Nitriles)
RN  - 0 (Pyridones)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Child
MH  - *Epilepsies, Partial/drug therapy
MH  - Anticonvulsants/adverse effects
MH  - Expert Testimony
MH  - Treatment Outcome
MH  - *Epilepsy/drug therapy
MH  - Asia
MH  - *Nitriles
MH  - *Pyridones
OTO - NOTNLM
OT  - Antiseizure medication
OT  - Asia
OT  - Pediatric epilepsies
OT  - Perampanel
OT  - Real-world experience
COIS- Declaration of competing interest Derrick Wei Shih Chan has participated in data 
      safety monitoring and/or advisory boards for Singapore Health Services and Eisai 
      and is President of the Singapore Epilepsy Society and the Singapore Epilepsy 
      Foundation. Surachai Likasitwattanakul has received speaker's honoraria from GSK, 
      Sanofi, Janssen, and Eisai. Akihisa Okumura has received speaker's honorarium 
      from Eisai. Benilda Sanchez-Gan has received speaker's honoraria from Abbott, 
      GlaxoSmithKline Philippines, HI-Eisai Pharmaceutical, Pediatrica, Sandoz 
      Philippines, Sun Pharma Philippines, and Torrent Pharma Philippines and is a 
      member of the Board of Trustees of the Child Neurology Society Philippines. 
      Sheffali Gulati, Wang-Tso Lee, Byung Chan Lim, Kam Tim Liu, and Yi Wang declare 
      no competing interests.
EDAT- 2023/12/03 00:41
MHDA- 2024/01/15 12:43
CRDT- 2023/12/02 18:01
PHST- 2023/04/27 00:00 [received]
PHST- 2023/09/08 00:00 [revised]
PHST- 2023/09/29 00:00 [accepted]
PHST- 2024/01/15 12:43 [medline]
PHST- 2023/12/03 00:41 [pubmed]
PHST- 2023/12/02 18:01 [entrez]
AID - S0887-8994(23)00350-8 [pii]
AID - 10.1016/j.pediatrneurol.2023.09.023 [doi]
PST - ppublish
SO  - Pediatr Neurol. 2024 Feb;151:5-16. doi: 10.1016/j.pediatrneurol.2023.09.023. Epub 
      2023 Oct 4.